WinonaTseMD

Neurology • New York, NY

Neurophysiology

Associate Professor of Neurology

Join to view full profile

Dr. Tse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tse's full profile

Already have an account?

Office
5 E 98th St
First Floor
New York, NY 10029
Phone+1 212-241-5607

Fax+1 212-241-3656

Summary

I am a neurologist specializing in movement disorders at the Mount Sinai Medical center.I graduated from the Brown University Program in Liberal Medical Education, did my Neurology Residency training at Mount Sinai Medical center and did a fellowship in Electromyography and Neurophysiology at Cornell University Medical center. I am devoted to providing excellent care to our patients with movement disorders and am happy to provide access to clinical trials and deep brain stimulation to our patients with Parkinson’s disease, essential tremor, dystonia and other movement disorders.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Clinical Neurophysiology, 1999 - 2000
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1996 - 1999
Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1995 - 1996
Stony Brook University Health Sciences Center School of MedicineClass of 1995

Certifications & Licensure

FL State Medical License 2020 - Present
NY State Medical License 1996 - 2026
PA State Medical License 2020 - 2022
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Mount Sinai Housestaff Award for Teaching Excellence Mount Sinai Neurology graduating residents, 2023
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover) Start of enrollment: 2020 Jul 30
Terminated
Phase 2
Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) Start of enrollment: 2018 Dec 10
Completed
Phase 2
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease Start of enrollment: 2015 Dec 29
Completed
Phase 2
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease Start of enrollment: 2011 Apr 01
Completed
Phase 2
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Start of enrollment: 2021 Oct 25
Recruiting
Phase 2, Phase 3
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease Start of enrollment: 2023 Nov 17
Recruiting
Phase 2
STEM-PD Open Label Extension (OLE) Start of enrollment: 2022 Sep 15
Enrolling by invitation
Not Applicable
STEM-Parkinson's Disease Start of enrollment: 2022 May 19
Recruiting
Not Applicable
Early Parkinson's Disease Monotherapy With CVN424 Start of enrollment: 2023 Sep 11
Recruiting
Phase 2
Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components Start of enrollment: 2021 Apr 28
Terminated
Phase 2
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease Start of enrollment: 2020 Dec 30
Active, not recruiting
Phase 2
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension Start of enrollment: 2018 Apr 10
Withdrawn
Phase 3
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease Start of enrollment: 2016 May 04
Active, not recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) Start of enrollment: 2024 Jun 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Andrea Quattrone, Nicolai Franzmeier, Hans-Jürgen Huppertz, Martin Klietz, Sebastian N Roemer
Movement Disorders. 2024-08-01
4 citations
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.
Cynthia L Comella, Joseph Jankovic, Robert A Hauser, Atul T Patel, Marta D Banach
Neurology. 2024-02-27
19 citations
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial.
Michael Camilleri, Thyagarajan Subramanian, Fernando Pagan, Stuart Isaacson, Ramon Gil
Annals of Internal Medicine. 2022-12-01

Professional Memberships

American Academy of Neurology - AAN
Member
Movement Disorders Society
Member
American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM
Member

Other Languages

Spanish, Chinese (Cantonese)